SGHT

Sight Sciences, Inc.

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.

Sight Sciences, Inc. (SGHT) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 B- (3.0) C+ (2.5) C+ (2.8) A (4.2) C+ (2.6) B- (3.0)
2026-11-07 B- (3.0) C (2.4) C+ (2.8) A (4.3) C+ (2.7) B- (3.0)
2026-10-31 B- (3.0) C (2.4) C+ (2.8) A+ (4.8) C+ (2.7) B- (3.1)
2026-10-24 B- (3.0) C (2.4) C+ (2.8) A+ (4.7) C+ (2.6) B- (3.1)

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe